Gynecologic Cancer
Conference Coverage
VIDEO: Pelvic radiation surpasses brachytherapy/chemo for early endometrial cancer
Pelvic radiation produced similar recurrence-free survival as vaginal brachytherapy plus chemo but with less toxicity and fewer local recurrences...
Conference Coverage
VIDEO: Everolimus/letrozole promising for recurrent endometrial cancer
NEW ORLEANS – Phase 2 results show unexpectedly high efficacy for everolimus/letrozole in chemotherapy-naive...
Gynecologic Oncology Consult
Same-day discharge for hysterectomy
Dr. Emma Rossi reviews how to best predict who is a good candidate for same-day discharge.
Conference Coverage
Chlamydia infections associated with more than a doubling of ovarian cancer risk
The presence of an antibody to chlamydia increased the chance of ovarian cancer by up to 2.25-fold in case-control studies in Poland and the U.S...
News
FDA authorizes first direct-to-consumer BRCA1/2 test
The test identifies the three most common BRCA1/2 mutations among people of Ashkenazi Jewish descent.
From the Journals
Avelumab safety compares with other checkpoint inhibitors
Although about two-thirds of patients had treatment-related adverse events, most experienced only mild or moderate ones.
Clinical Review
2018 Update on gynecologic cancer
Gynecologic malignancies remain a major cause of morbidity and mortality. In this article: latest cervical cancer screening recommendations from...
Gynecologic Oncology Consult
Telling her she has cancer: A patient-centered approach to breaking bad news
The SPIKES approach is a helpful tool for applying consistent principles to the needs of individual patients.
News
FDA approves new HPV assay
The assay even tests for the HPV genotypes associated with two-thirds of cervical cancers.
Latest News
USPSTF: Routine screens for ovarian cancer not recommended
USPSTF issues final recommendation against routine screens, citing risk for unnecessary surgeries.
From the Journals
Letrozole promising as maintenance treatment for high-grade serous ovarian cancer
Patients who received letrozole after debulking surgery and platinum-based chemotherapy had a significantly prolonged recurrence-free interval.